Tyvaso (Treprostinil) Patent Expiration, LOE Window & CMS Spending

Tyvaso (Treprostinil) by United Therapeutics: FDA Orange Book core substance LOE 2028-12-15 (last listed 2042-02-03), 0 AB generics, $158K 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUnited Therapeutics
FDA Application & PathwayN022387 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2028-12-15
Last Listed Patent or Exclusivity Date2042-02-03
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$158K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$158K
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 17.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for United Therapeutics across sibling Meru public-data platforms.